An interventional study of Comprehensive geriatric assessment (CGA) and treatment in Hematologic Malignancy, Treatment Adherence and Treatment Complication, sponsored by Odense University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Hematologic Neoplasms with a site in Denmark — 12 open to participants now, 13 under way, 2 of them phase 3. Hematologic Neoplasms · Denmark.
Among the 26 studies in Hematologic Neoplasms with a site in Denmark, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 with no phase, reaches primary completion later than 1 of the 12 other live ones, and was the 20th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →12 of the 26 studies in Hematologic Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:
CSL Behring · Sites in Denmark, United States, Belgium and 8 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Denmark, United States, Australia and 4 more countries
Ages 18+
Incyte Corporation · Sites in Denmark, United States, Australia and 2 more countries
Ages 18+
Immunome, Inc. · Sites in Denmark, United States, France and 1 more country
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 152 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 110 across the 21 interventional studies, 300 across the 5 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 26 have an industry lead sponsor. The 10 most frequent:
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Odense University Hospital has 3 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Hematologic Neoplasms with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06377059Rigshospitalet, DenmarkEarly Detection of Complications During Immunotherapy for Haematological Malignancy | 2026-12-01 |
| NCT07634263Odense University HospitalWhy Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Hematologic Neoplasms with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Improve study is a randomized controlled trial investigating the efficacy of adding comprehensive geriatric assessment and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention comprehensive geriatric assessment and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation of comorbidity and frailty as is usual standard at Department of Hematology. Primary endpoint is elderly functional Index at 12 weeks.
RESEARCH PLAN
STUDY DESIGN IMPROVE aims to investigate the efficacy of adding comprehensive geriatric assessment (CGA) and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention CGA and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation as well as management of comorbidity, frailty and needs as is the current standard at Departments of Hematology.
PARTICIPANTS AND TIMELINES One hundred and fifty two patients complying with inclusion and exclusion criteria detailed below will be recruited at participating Hematological Departments in Denmark. Study period is 52 weeks for each study participant.
INTERVENTIONS AND ASSESSMENTS Hematological treatment plan Study participants will be given a hematological cancer treatment plan according to standard guidelines at the discretion of the treating physician at the Department of Hematology. The hematological treatment plan will not be altered because of participation in IMPROVE study. Data on whether the cancer treatment is prescribed with a reduced dose-intensity due to frailty or later reduced due to toxicity will be collected.
CGA and treatment CGA and treatment will be performed before or after initiation of hematological cancer treatment, and within 6 weeks from inclusion. Performing CGA shall not delay initiation of hematological cancer treatment if immediate treatment is necessary. A geriatrician together with a geriatric nurse will perform CGA at the Department of Geriatric Medicine. CGA is more thoroughly described elsewhere in this report. Based on CGA findings, the geriatrician will initiate relevant further investigation(s), intervention(s) and treatment(s) if indicated.
Assessment of functional status The investigators will record the patients exercise habits via a short interview with the patient. The interview contains two questions concerning exercise habits derived from the Survey of Health, Ageing and Retirement in Europe (SHARE). Furthermore objective simple physical muscle strength tests will be applied to assess upper and lower extremity functioning.
Physical tests Physical tests will be assessed at baseline and at 12 and 26 weeks follow-up. Physical tests will be 30 seconds chair stand test (30s-CST) and handgrip strength
Treatment toxicity and adherence to the hematological treatment plan
Data will be collected at the beginning of each treatment cycle until 26 weeks after inclusion. The following data will be collected:
Review of medications Information about polypharmacy (more than 5 daily drugs) will be collected from patients´ personal electronic file of prescriptions and medication purchases at baseline and at 12- and 26-week follow-up.
Hospitalization and survival Patients will be followed through a review of medical records for number and duration of unplanned hospitalizations and overall, and cancer-specific survival at 26- and 52-week follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Comprehensive Geriatric Assessment and treatment
Other: Comprehensive geriatric assessment (CGA) and treatment
Standard hematological evaluation of comorbidity and needs during hematological cancer treatment.
CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include: * Assessment of comorbidity and treatments * Review of medications including potential adjustment * Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue * Objective examination including blood tests and electrocardiogram * Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires * Assessment of domestic conditions, including need for assistance * Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required
Elderly functional Index
The Elderly Functional Index (ELFI) is calculated using the physical functioning, role functioning, and social functioning of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) core 30, and the mobility item of the EORTC-QLQ-elderly 14 (ELD14) questionnaire. ELFI is calculated at baseline and at 12- and 26- week follow-up. Maximum value of ELFI is 100. Minimum value of ELFI is 0. Higher score indicates higher function.
Time frame: 12 and 26 weeks after inclusion
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
The questionnaire contains functional and symptom subscales. Maximum value for scales is 100 and minimum values is 0. A higher score indicates higher function for functional scales and more symptoms for symptom scales.
Time frame: 12 and 26 weeks after inclusion
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Elderly14 (EORTC QLQ-Eld14).
The questionnaire contains functional scales and symptom scales. Maximum value for scales is 100 and minimum values is 0. A higher score indicates higher function for functional scales and more symptoms for symptom scales
Time frame: 12 and 26 weeks after inclusion
Handgrip strength
Handgrip strength is measured in kilograms with a handgrip dynamometer
Time frame: 12 and 26 weeks after inclusion
30-second chair stand test
30-second chair stand test is measured in number of stand-up-and-sit-downs in 30 seconds
Time frame: 12 and 26 weeks after inclusion
Treatment toxicity
Endpoint is assessed as prevalence of grade \> 1 adverse events according to Common Terminology Criteria for Adverse Events Version 5.0 at baseline, 12 and 26 weeks after inclusion
Time frame: Baseline, 12 and 26 weeks after inclusion
Adherence to hematological cancer treatment
Alterations to original cancer treatment plan yes/no
Time frame: 12 and 26 weeks after inclusion
Polypharmacy yes/no
Polypharmacy is defined as use of 5 or more daily medications
Time frame: 12 and 26 weeks after inclusion
Unplanned hospital admissions
rates and hospital days
Time frame: 26 and 52 weeks after inclusion
Overall and cancer specific survival
survival proportion and cancer specific survival proportion
Time frame: 26 and 52 weeks after inclusion
Plan to share: No — The IPD sharing plan is to assess the possibility of publishing IPD or part of IPD in a way that is allowed taken GDPR into account.
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Mar 2026, 23 months after the start.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 23 months is below that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.